An update on clinical trials for chemoprevention of human skin cancer

Abstract

The pathophysiology of skin cancer is complex, with multiple factors contributing to its development. The proactive treatment of skin cancer has been investigated in the form of chemoprevention of cutaneous malignancies in clinical trials. Chemoprevention is the use of natural or pharmacologic agents that prevent or reverse skin cancer development. Multiple trials have arisen over the past decades to explore the efficacy of specific agents to halt the progression of UV radiation damage. This comprehensive review article aims to assess clinical trials performed with chemopreventive agents for melanoma and nonmelanoma skin cancers. The following compounds were most often used in these trials: nicotinamide, retinoids, polyphenolic antioxidants, COX-2 selective inhibitors, non-steroidal anti-inflammatory drugs, difluoromethylornithine, and 5-fluorouracil. Many agents show promise in their ability to prevent nonmelanoma skin cancer formation, with few melanoma trials demonstrating efficacy. The chemoprevention efforts aimed at skin cancer are complex; current and future trials will be instrumental in identifying therapeutic agents that pose efficacy in halting cancer development and assessing whether long-term administration is tolerable.

Keywords

Skin cancer / chemoprevention / melanoma / non-melanoma skin cancer / chemopreventive agents

References

[1] Gordon R.Skin cancer: an overview of epidemiology and risk factors.Semin Oncol Nurs2013;29:160-9

[2] Stern RS.Prevalence of a history of skin cancer in 2007.Arch Dermatol2010;146:279-82

[3] American Cancer Society. Key statistics for melanoma skin cancer. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html [Last accessed on 24 Feb 2023]

[4] Narayanan DL,Fox JL.Ultraviolet radiation and skin cancer.Int J Dermatol2010;49:978-86

[5] Benjamin CL.p53 and the pathogenesis of skin cancer.Toxicol Appl Pharmacol2007;224:241-8 PMCID:PMC2080850

[6] Meeran SM,Katiyar SK.IL-12 deficiency exacerbates inflammatory responses in UV-irradiated skin and skin tumors.J Invest Dermatol2008;128:2716-27 PMCID:PMC2574589

[7] Kennedy C,Willemze R.The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer.J Invest Dermatol2003;120:1087-93

[8] Ma F,Hu S.Skin cancer awareness and sun protection behaviors in white Hispanic and white non-Hispanic high school students in Miami, Florida.Arch Dermatol2007;143:983-8

[9] Beissert S.Mechanisms involved in ultraviolet light-induced immunosuppression.J Investig Dermatol Symp Proc1999;4:61-4

[10] Stratton SP,Alberts DS.Promising agents for chemoprevention of skin cancer.Curr Oncol2006;13:185-6 PMCID:PMC3394601

[11] Ho WL.Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients.Br J Dermatol2008;158:217-24

[12] Wright TI,Flowers FP.Chemoprevention of nonmelanoma skin cancer.J Am Acad Dermatol2006;54:933-46; quiz 947

[13] Fischer SM,Gordon GB.Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.Mol Carcinog1999;25:231-40

[14] Dorr RT,Brooks C.Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-d-Phe7]-α-MSH in humans.Photochem Photobiol2000;72:526

[15] Stratton SP,Alberts DS.The state-of-the-art in chemoprevention of skin cancer.Eur J Cancer2000;36:1292-7

[16] Nemer KM.Topical and systemic modalities for chemoprevention of nonmelanoma skin cancer.Dermatol Clin2019;37:287-95

[17] Sacco AG.Adjuvant and neoadjuvant treatment of skin cancer.Facial Plast Surg Clin N Am2019;27:139-50

[18] Athar M,Kopelovich L.Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.Arch Biochem Biophys2011;508:159-63 PMCID:PMC3063391

[19] De Felice F,De Falco D.Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery.Int J Dermatol2022;61:911-5 PMCID:PMC9543629

[20] Wehner MR,Parvataneni R,Boscardin WJ.Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma.JAMA Dermatol2015;151:382-8

[21] Uzarska M,Schwartz RA,Zegarska B.Chemoprevention of skin melanoma: facts and myths.Melanoma Res2013;23:426-33

[22] Nikas IP,Ryu HS.The role of nicotinamide in cancer chemoprevention and therapy.Biomolecules2020;10:477 PMCID:PMC7175378

[23] Minocha R,Halliday GM.Melanoma and nonmelanoma skin cancer chemoprevention: a role for nicotinamide?.Photodermatol Photoimmunol Photomed2018;34:5-12

[24] Niren N.Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review.Cutis2006;77:11-6

[25] Gensler HL.Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide.Nutr Cancer1997;29:157-62

[26] Yiasemides E,Halliday GM,Damian DL.Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans.Carcinogenesis2009;30:101-5

[27] Surjana D,Martin AJ,Damian DL.Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.J Invest Dermatol2012;132:1497-500

[28] Chen AC,Choy B.A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention.N Engl J Med2015;373:1618-26

[29] Martin AJ,Vardy JL.Neurocognitive function and quality of life outcomes in the ONTRAC study for skin cancer chemoprevention by nicotinamide.Geriatrics2019;4:31 PMCID:PMC6473406

[30] Chen AC,Dalziell RA.A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.Br J Dermatol2016;175:1073-5

[31] Drago F,Cogorno L,Marsano LA.Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.Eur J Dermatol2017;27:382-5

[32] Einspahr JG,Bowden GT.Chemoprevention of human skin cancer.Crit Rev Oncol Hematol2002;41:269-85

[33] Sheng H,Morrow J.Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.Cancer Res1998;58:362-6.

[34] Buckman SY,Hale P.COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.Carcinogenesis1998;19:723-9

[35] An KP,Tang X.Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.Photochem Photobiol2002;76:73

[36] Orengo IF,Phillips R,Lewis AT.Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model.Arch Dermatol2002;138:751-5

[37] Pentland AP,Scott GA,Han R.Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.Carcinogenesis1999;20:1939-44

[38] Higashi Y,Kanzaki T.Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression.Int J Cancer2000;86:667-71

[39] Elmets CA,Pentland AP.Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.J Natl Cancer Inst2010;102:1835-44 PMCID:PMC3001966

[40] Zhan H.The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention.Am J Clin Dermatol2007;8:195-200

[41] Kuźbicki L,Chwirot BW.Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.Melanoma Res2006;16:29-36

[42] Tudor DV,Lupu M.COX-2 as a potential biomarker and therapeutic target in melanoma.Cancer Biol Med2020;17:20-31 PMCID:PMC7142851

[43] Ellebaek E,Iversen TZ.Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.Cancer Immunol Immunother2012;61:1791-804

[44] Prostaglandin inhibition and immune checkpoint blockade in melanoma - study results. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03396952?term=cox-2&cond=Melanoma&view=results [Last accessed on 24 Feb 2023]

[45] Kumar D,Tyagi E.Aspirin Suppresses PGE₂ and activates AMP kinase to inhibit melanoma cell motility, pigmentation, and selective tumor growth in vivo.Cancer Prev Res2018;11:629-42 PMCID:PMC6751568

[46] Kong R,Fisher GJ.A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin.J Cosmet Dermatol2016;15:49-57

[47] Niles RM.The use of retinoids in the prevention and treatment of skin cancer.Expert Opin Pharmacother2002;3:299-303

[48] Misiewicz J,Golebiowska A,Czarnetzki BM.Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study.J Am Acad Dermatol1991;24:448-51

[49] Moon T,Cartmel B.Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial.Cancer Epideliol Biomarkers Prev1997;6:949-56

[50] Levine N,Cartmel B.Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.Cancer Epidemiol Biomarkers Prev1997;6:957-61.

[51] Tangrea JA,Taylor PR.Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group.J Natl Cancer Inst1992;84:328-32

[52] Kadakia KC,Loprinzi CL.Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251).Cancer2012;118:2128-37 PMCID:PMC3365547

[53] Perez HC,Perez JS.Basic aspects of the pathogenesis and prevention of non-melanoma skin cancer in solid organ transplant recipients: a review.Int J Dermatol2017;56:370-8

[54] Graaf YGL, Euvrard S, Bavinck JNB. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients.Dermatol Surg2004;30:656-61

[55] Sévaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin.J Am Acad Dermatol2003;49:407-12

[56] George R,Russ GR,Mathew TH.Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients.Australas J Dermatol2002;43:269-73

[57] Lien MH,Glass LF.Advances in the chemoprevention of non-melanoma skin cancer in high-risk organ transplant recipients.Semin Oncol2012;39:134-8

[58] Francz PI,Biesalski HK.Modulation of UVA-induced lipid peroxidation and suppression of UVB-induced ornithine decarboxylase response by all-trans-retinoic acid in human skin fibroblasts in vitro.Biol Chem1998;379:1263-9

[59] Pegg AE,Coleman CS.Ornithine decarboxylase as a target for chemoprevention.J Cell Biochem Suppl1995;22:132-8

[60] Kreul SM,Kim K.A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.Cancer Prev Res2012;5:1368-74 PMCID:PMC3518692

[61] Elmets CA.Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.Cancer Prev Res2010;3:8-11 PMCID:PMC2926793

[62] Tang X,Feith DJ.Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice.J Clin Invest2004;113:867-75 PMCID:PMC362123

[63] Gilmour SK.Polyamines and nonmelanoma skin cancer.Toxicol Appl Pharmacol2007;224:249-56 PMCID:PMC2098876

[64] Chen AC,Halliday GM.Oral and systemic photoprotection.Photodermatol Photoimmunol Photomed2014;30:102-11

[65] Bailey HH,Verma AK.A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.Cancer Prev Res2010;3:35-47 PMCID:PMC2804946

[66] Einsphar J,Alberts D.Skin cancer chemoprevention: strategies to save our skin.Recent Results Cancer Res2003;163:151-266

[67] Jeter JM,Stratton SP.Phase IIB randomized study of topical difluoromethylornithine and topical diclofenac on sun-damaged skin of the forearm.Cancer Prev Res2016;9:128-34 PMCID:PMC4778979

[68] Meyskens FL Jr,Pelot D.Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.Cancer Prev Res2008;1:32-8

[69] Carbone P,Thomas J.Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.Cancer Epidemiol Biomarkers Prev2001;10:657-61

[70] Yang CS.Tea and cancer.J Natl Cancer Inst1993;85:1038-49

[71] Islam SU,Ahsan H.An update on the role of dietary phytochemicals in human skin cancer: new insights into molecular mechanisms.Antioxidants2020;9:916 PMCID:PMC7600476

[72] Gensler HL,Valcic S.Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea.Nutr Cancer1996;26:325-35

[73] Chen W,Valcic S,Bowden GT.Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line.Mol Carcinog1999;24:79-84

[74] Ellis LZ,Luo Y.Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion.Biochem Biophys Res Commun2011;414:551-6 PMCID:PMC3430966

[75] Zhang J,Huang Z.Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.Oncotarget2016;7:79557-71 PMCID:PMC5346735

[76] Mukhtar H.Green tea in chemoprevention of cancer.Toxicol Sci1999;52:111-7

[77] Farrar MD,Clarke KA.A randomized controlled trial of green tea catechins in protection against ultraviolet radiation-induced cutaneous inflammation.Am J Clin Nutr2015;102:608-15 PMCID:PMC4548173

[78] Ng CY,Hsiao HY.Phytochemicals in skin cancer prevention and treatment: an updated review.Int J Mol Sci2018;19:941 PMCID:PMC5979545

[79] Goodman JR.Aspirin and other NSAIDs as chemoprevention agents in melanoma.Cancer Prev Res2014;7:557-64 PMCID:PMC4049124

[80] Weinstock MA,Siegel JA.Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial.JAMA Dermatol2018;154:167-74 PMCID:PMC5839275

[81] Cunningham TJ,Eliane JP.Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.J Clin Invest2017;127:106-16 PMCID:PMC5199703

[82] Endrizzi B,Ray T,Lee P.Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.Dermatol Surg2013;39:634-45